Novel BCL-2 Inhibitor Lisaftoclax in Relapsed or Refractory Chronic Lymphocytic Leukemia and Other Hematologic Malignancies: First-in-Human Open-Label Trial

Ailawadhi, S; Chen, Z; Huang, B; Paulus, A; Collins, MC; Fu, L; Li, MY; Ahmad, M; Men, L; Wang, HB; Davids, MS; Liang, ER; Mekala, DJ; He, ZC; Lasica, M; Yannakou, CK; Parrondo, R; Glass, L; Yang, DJ; Chanan-Khan, A; Zhai, YF

Zhai, YF (通讯作者)，Ascentage Pharm Grp Inc, Rockville, MD USA.;Zhai, YF (通讯作者)，Ascentage Pharm Grp Inc, 700 King Farm Blvd, Suite 510, Rockville, MD 20850 USA.;Chanan-Khan, A (通讯作者)，Mayo Clin, Canc Ctr, Jacksonville, FL 32224 USA.

CLINICAL CANCER RESEARCH, 2023; 29 (13): 2385

Abstract

Purpose: This global phase I trial investigated the safety, efficacy, pharmacokinetics, and pharmacodynamics of lisaftoclax (APG-2575), a novel, orall......

Full Text Link


Links

期刊讨论 | 中国SCI论文 | 期刊主页 | 投稿经验 | 杂志官网 | 投稿链接 | 作者需知 | PMC链接 | Pubmed全文检索